Key Takeaways
- Commonly used doses are 200-500 mcg per injection, once or twice daily, but these figures come from clinical practice and vendor convention rather than from a dose-finding trial.
- Human evidence is thin, not absent. A 2025 review in Current Reviews in Musculoskeletal Medicine found only three pilot studies in humans, covering intraarticular knee pain, interstitial cystitis, and intravenous safety.[1]
- BPC-157 is not an FDA-approved drug. It was placed in FDA Category 2 in 2023, removed in April 2026 after the nomination was withdrawn, and recommended for the 503A Bulks List by the FDA's advisory committee in July 2026 — but that recommendation is non-binding and compounding is still not authorised.
- It is banned in sport. WADA added BPC-157 to its Prohibited List in 2022, so competitive athletes should treat any use as a positive test.
- Most published work is in rodents. The regenerative findings that make BPC-157 popular are real, but they are animal findings, and animal doses do not convert cleanly to human ones.
BPC-157 Dosage Chart
The figures below are the ranges reported in clinical practice and by compounding pharmacies. They are a description of what people use, not a recommendation, and no trial has validated them.
| Goal | Typical dose | Frequency | Common duration |
|---|---|---|---|
| General recovery | 200-300 mcg | Once daily | 4-6 weeks |
| Soft-tissue or tendon injury | 250-500 mcg | Once or twice daily | 6-8 weeks |
| Gut and gastrointestinal support | 250-500 mcg | Once daily, oral | 4-8 weeks |
| Post-surgical recovery | 300-500 mcg | Twice daily | 4-6 weeks |
| Maintenance after an injury cycle | 200 mcg | Once daily or alternate days | As directed |
Two patterns hold across almost every protocol. Doses cluster in the low hundreds of micrograms rather than milligrams, and injections are usually placed near the site of injury on the theory of local action, though systemic distribution means this is convention rather than established practice.
How to Calculate Your Dose in mL and Units
This is where most dosing mistakes happen, because vials are labelled in milligrams and doses are discussed in micrograms. There are 1,000 mcg in 1 mg, so a 5 mg vial holds 5,000 mcg.
On a U-100 insulin syringe, 100 units is 1 mL. The arithmetic is:
- Concentration = vial strength divided by the bacteriostatic water added
- Units to draw = dose divided by concentration, multiplied by 100
| Vial | Bacteriostatic water | Concentration | 250 mcg dose | 500 mcg dose |
|---|---|---|---|---|
| 5 mg | 2 mL | 2,500 mcg/mL | 10 units | 20 units |
| 5 mg | 5 mL | 1,000 mcg/mL | 25 units | 50 units |
| 10 mg | 2 mL | 5,000 mcg/mL | 5 units | 10 units |
| 10 mg | 5 mL | 2,000 mcg/mL | 12.5 units | 25 units |
If you would rather not do the arithmetic by hand, our peptide reconstitution calculator works out concentration and draw volume for any vial and dose, the BAC water calculator helps you pick a diluent volume, and the units converter translates between mcg, mg, mL and syringe units.
Does BPC-157 Dosage Depend on Body Weight?
This question comes up constantly, usually framed as a specific figure for a 200 lb male, so it deserves a direct answer.
Most practical BPC-157 protocols are fixed-dose, not weight-based. A 140 lb person and a 220 lb person are typically given the same 250 or 500 mcg. That is not because body weight is irrelevant in principle; it is because no human dose-finding study exists to establish a mcg-per-kilogram figure, so there is nothing to scale.
Weight-based numbers do circulate, generally around 1-10 mcg per kilogram, and they are usually back-calculated from rodent studies. That conversion is unreliable. Allometric scaling from rats to humans is not a simple multiplication, and applying it to a peptide with no human pharmacokinetic anchor produces a figure with false precision. If you see a calculator that outputs a confident weight-based BPC-157 dose, understand that the confidence is manufactured.
For a 200 lb (91 kg) adult, the practical answer is that the same 250-500 mcg range applies as for anyone else.
BPC-157 Dosage by Use Case
Tendon, Ligament and Muscle Injury
This is the most common reason people seek BPC-157 out, and the rodent evidence behind it is genuinely substantial: accelerated healing of transected Achilles tendon, medial collateral ligament and muscle in multiple models, with angiogenesis via the VEGFR2 and Akt-eNOS pathways as the proposed mechanism.[1][2] Typical practice is 250-500 mcg daily for 6-8 weeks. See our tissue repair and recovery overview for how clinics approach this goal more broadly.
The honest caveat is that the single human musculoskeletal pilot study examined intraarticular injection for knee pain, not tendon healing.[1]
Gastrointestinal Use
The gut is where BPC-157 has the strongest human claim, because the peptide was originally derived from gastric juice and was developed by Pliva as PL-14736 specifically for inflammatory bowel disease. That programme reported it to be safe in clinical trials.[3] It did not complete development into an approved drug.
Oral dosing is usually 250-500 mcg daily. Unusually for a peptide, oral administration is plausible here rather than pointless, because BPC-157 is notably stable in gastric juice and the target tissue is the gut itself.
Post-Surgical Recovery
Practice tends toward the upper end, 300-500 mcg twice daily for four to six weeks. There is no human trial supporting perioperative use, and anyone recovering from surgery should raise it with their surgeon rather than adding it quietly, since angiogenic effects are not universally desirable during healing.
Injection, Oral or Nasal Spray?
Subcutaneous injection is the most common route. Injections are typically placed in the abdomen or near the injury site, rotating locations to avoid irritation.
Oral capsules and liquids are the second most common. As above, this is a reasonable route for gut-directed goals and a much weaker one for a distant tendon, since systemic absorption of an oral peptide is limited.
Nasal sprays are marketed mainly for cognitive or neurological goals. There is no human dosing evidence for intranasal BPC-157 at all, and the dose delivered per spray varies widely between products.
Reconstituting a BPC-157 Vial
BPC-157 arrives as a lyophilised powder, usually in 5 mg or 10 mg vials.
Add bacteriostatic water slowly against the inside wall of the vial rather than directly onto the powder, then swirl gently. Do not shake: peptides are sensitive to mechanical stress and shaking can degrade them. The powder should dissolve within a minute or two into a clear solution. Discard it if it stays cloudy or shows particulates.
Our step-by-step reconstitution guide covers the technique in more detail.
Store the unreconstituted powder in a freezer and the reconstituted vial in a refrigerator, where it is generally considered stable for two to four weeks. Keep it away from light.
BPC-157 and TB-500 Blend Dosing
Blends of BPC-157 and TB-500 are searched at least as heavily as BPC-157 on its own, and they are a different dosing question because TB-500 uses a milligram-scale dose while BPC-157 uses a microgram-scale one.
The common pattern is BPC-157 at 250-500 mcg daily alongside TB-500 at 2-5 mg per week, often split into two injections. The rationale offered is complementary mechanisms — BPC-157 for angiogenesis, TB-500 for cell migration — and it has no human trial behind it.
If you are dosing a specific blend rather than two separate vials, the ratio in the product determines everything, and the arithmetic is different from dosing either peptide alone. We cover the common ones in detail:
- BPC-157 and TB-500 blend dosage guide
- BPC-157, TB-500, KPV and GHK-Cu 80 mg KLOW blend dosage guide
- BPC-157, TB-500 and GHK-Cu GLOW blend dosage guide
What the Human Evidence Actually Shows
This section exists because the gap between how BPC-157 is marketed and what has been demonstrated in people is unusually wide.
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine surveyed the literature and concluded that despite broad preclinical support, human data are extremely limited, with only three pilot studies: intraarticular injection for knee pain, interstitial cystitis, and an intravenous safety and pharmacokinetics study.[1] Separately, the Pliva PL-14736 programme took BPC-157 into inflammatory bowel disease trials and reported it as safe.[3]
So the accurate statement is not that BPC-157 is untested in humans. It is that the human record consists of a handful of small studies and an abandoned drug development programme, none of which established the doses in the chart above. Every milligram figure in circulation is convention.
Is BPC-157 Legal?
BPC-157 is not approved by the FDA for any indication.
BPC-157's regulatory position has changed twice recently, and most pages describing it are out of date.
In September 2023 the FDA placed BPC-157 in Category 2 of its interim 503A bulk drug substances list — the category for substances raising significant safety risks. That closed off legal compounding and pushed BPC-157 into being sold overwhelmingly as a "research chemical" rather than through the clinic channel supplying many other peptides.
On 22 April 2026 it was removed from Category 2, along with eleven other peptides including TB-500, because the nominations were withdrawn — not because the FDA determined it was safe. Then on 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for inclusion on the 503A Bulks List, going against FDA staff's own written recommendation.
What that does and does not mean is worth stating precisely, because it is widely misreported. The committee's vote is advisory and non-binding. Adding a substance to the Bulks List requires separate notice-and-comment rulemaking, which historically takes upwards of a year. Until that completes, BPC-157 is not FDA-approved, is not on the Bulks List, and is not authorised for compounding. Our coverage of the July 2026 vote walks through the process in detail.
It is not a controlled substance, so possession is not a criminal matter. The regulatory pressure sits on manufacture and sale for human use.
If you would rather work with a supervising provider than source it yourself, our clinic finder lists peptide clinics by location.
WADA added BPC-157 to the Prohibited List in 2022 under the non-approved substances category, in and out of competition. Any tested athlete should treat it as disqualifying.
